Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Bayer's (BAYRY) investigational candidate, finerenone, meets primary endpoint in the phase III FIDELIO_DKD study in patients with CKD and T2D.

Bayer's Drug Meets Primary Endpoint in Renal Outcomes Study

Bayer has agreed to delay part of a proposed settlement of allegations that its widely used weedkiller Roundup caused cancer after a U.S. judge questioned its plan to deal with future claims.

Bayer puts part of Roundup settlement on hold

Bayer shares dropped 6% on Tuesday after a U.S. judge questioned the German company's proposed settlement to deal with future claims relating to allegations that its widely-used weedkiller Roundup caused cancer.

Bayer shares tumble after judge questions part of Roundup settlement

There is a major drama playing out in farm country involving glyphosate, the broad-spectrum systemic herbicide and crop desiccant.

Bayer To Pay More Than $10 Billion In Roundup Settlement

Bayer AG (OTC: BAYRY) will pay between $10.1 to $10.9 billion to resolve litigation over the weedkiller Roundup.

Bayer Settles Most Cases Related To Roundup Herbicide For Up To $10.9B

Seeking to forestall further claims, Bayer AG is taking a risky bet that an independent scientific review will ultimately show that its widely used weed killer Roundup does not cause cancer, legal experts said.

Bayer bets on science in bid to prevent future Roundup lawsuits: legal experts

The plaintiffs said the weedkiller caused their cancers. Bayer became the defendant after acquiring its manufacturer, Monsanto, for $63 billion in 2018.

Bayer Settles Roundup Lawsuit for Almost $11 Billion

Bayer will pay more than $10 billion to resolve thousands of lawsuits regarding claims that its herbicide Roundup causes cancer, the company announced Wednesday.

Bayer reaches over $10 billion settlement in Roundup cancer lawsuits

Numerous lawsuits have been brought against the pharmaceutical subsidiary over claims the chemical causes cancer

Bayer agrees to $10.9bn settlement over Monsanto’s weedkiller Roundup

“It’s rare that we see a consensual settlement with that many zeros on it.”

Bayer To Pay Up To $10.9 Billion To Settle Cancer Claims Over Roundup

Bayer AG on Wednesday said it agreed to settle U.S. lawsuits claiming that its widely-used weedkiller Roundup caused cancer for $10.1-10,9 billion.

Bayer settles Roundup cancer lawsuits for up to $10.9 billion

Weitz & Luxenberg said on Wednesday it and other law firms reached a settlement with Bayer on behalf of almost one hundred thousand Americans who had been diagnosed with cancer after exposure to Monsanto's Roundup weedkiller.

Law firm Weitz & Luxenberg says has reached Glyphosate settlement with Bayer

Germany's Bayer is set to reach a settlement this week with U.S. plaintiffs that claim its glyphosate-based weedkillers cause cancer, two people familiar with the matter told Reuters.

Bayer nears glyphosate settlement after lengthy talks: sources

Shares of Bayer BAYN, +6.97% climbed 6% as Handelsblatt reported the chemicals giant may reach a settlement between $8 billion and $10 billion to settle claims the Roundup weedkiller causes cancer.

Bayer shares rally on report it's near Roundup settlement that could be $10 billion

Bayer AG is close to agreeing a settlement worth $8-10 billion with plaintiffs in a case over its glyphosate-based weedkiller, German business daily Handelsblatt reported on Tuesday.

Bayer close to glyphosate settlement worth $8-10 billion: Handelsblatt

Bayer AG won a court ruling blocking California from requiring the German-based company to tell consumers that a chemical in its Roundup herbicide is known to cause cancer, Bloomberg News reported on Monday.

Bayer wins court ruling restricting California's Roundup warning: Bloomberg News

Bayer AG said on Tuesday it will scrap a nearly $1 billion project to produce the chemical dicamba in the United States, but said the move is unrelated to a federal court decision that blocked sales of weed killers based on the product.

Bayer scraps U.S. plans to produce crop chemical blocked by court

Bayer (BAYRY) initiates a phase III study to evaluate finerenone compared to placebo in more than 5,500 symptomatic heart failure patients with a left ventricular ejection fraction.

Bayer Initiates a Phase III Study in Heart Failure Patients

Bayer shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.
The post Bayer Shows Rising Price Performance With Jump To 82 RS Rating appeared first on Investor's Business Daily.

Bayer Shows Rising Price Performance With Jump To 82 RS Rating

eBay

Helen of Troy

Labcorp Holdings Inc

Parker-Hannifin

While P/E alone fails to identify a true value stock, PEG helps to find the intrinsic value of a stock.

5 PEG-Based Value Stocks to Buy Amid the Coronavirus Crisis

Bayer is arguably the cheapest large-cap pharma stock investors have ever seen -- but can the company keep a key risk at bay?

Is Bayer Stock a Buy?

Elanco Animal Health Inc

Elanco Animal Health  secured EU antitrust clearance on Monday to buy Bayer's  veterinary drugs unit after pledging to sell some products to address competition concerns about the $7.6 billion deal.

Elanco wins conditional EU antitrust okay for $7.6 billion Bayer deal

Bayer (BAYRY) seeks approval of chronic heart failure drug, vericiguat, in the EU and Japan.

Bayer (BAYRY) Submits Applications for Heart Failure Drug

Bayer AG  has been blocked from selling an agricultural weed killer in the United States, the latest setback for a business already fighting an expensive legal battle over another product.

U.S. court blocks sales of Bayer weed killer

German agrochemicals group Bayer AG has been blocked from selling its dicamba-based weed killer in the United States after an appeals court rejected a federal regulator's permit for the product.

News for Bayer AG Stock (BAYRY)